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Chetan Deshpande2, Kuang-Hung Pan4, Richard Lin4, Chih-Jian Lih4, Sheng-Yung P Chang3, Tzielan Lee5,
Christy Sandborg5, Ann B Begovich3, Stanley N Cohen4 and Elizabeth D Mellins2,5*
Abstract
Background: Clinicians have long appreciated the distinct phenotype of systemic juvenile idiopathic arthritis (SJIA)
compared to polyarticular juvenile idiopathic arthritis (POLY). We hypothesized that gene expression profiles of
peripheral blood mononuclear cells (PBMC) from children with each disease would reveal distinct biological
pathways when analyzed for significant associations with elevations in two markers of JIA activity, erythrocyte
sedimentation rate (ESR) and number of affected joints (joint count, JC).
Methods: PBMC RNA from SJIA and POLY patients was profiled by kinetic PCR to analyze expression of 181 genes,
selected for relevance to immune response pathways. Pearson correlation and Student’s t-test analyses were
performed to identify transcripts significantly associated with clinical parameters (ESR and JC) in SJIA or POLY
samples. These transcripts were used to find related biological pathways.
Results: Combining Pearson and t-test analyses, we found 91 ESR-related and 92 JC-related genes in SJIA. For
POLY, 20 ESR-related and 0 JC-related genes were found. Using Ingenuity Systems Pathways Analysis, we identified
SJIA ESR-related and JC-related pathways. The two sets of pathways are strongly correlated. In contrast, there is a
weaker correlation between SJIA and POLY ESR-related pathways. Notably, distinct biological processes were found
to correlate with JC in samples from the earlier systemic plus arthritic phase (SAF) of SJIA compared to samples
from the later arthritis-predominant phase (AF). Within the SJIA SAF group, IL-10 expression was related to JC,
whereas lack of IL-4 appeared to characterize the chronic arthritis (AF) subgroup.
Conclusions: The strong correlation between pathways implicated in elevations of both ESR and JC in SJIA argues
that the systemic and arthritic components of the disease are related mechanistically. Inflammatory pathways in
SJIA are distinct from those in POLY course JIA, consistent with differences in clinically appreciated target organs.
The limited number of ESR-related SJIA genes that also are associated with elevations of ESR in POLY implies that
the SJIA associations are specific for SJIA, at least to some degree. The distinct pathways associated with arthritis in
early and late SJIA raise the possibility that different immunobiology underlies arthritis over the course of SJIA.
Keywords: Arthritis, Inflammation, Juvenile idiopathic arthritis (JIA), Systemic JIA, Polyarticular JIA, Transcriptional
analysis
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Background
Systemic juvenile idiopathic arthritis (SJIA) is currently
classified as a subtype of juvenile idiopathic arthritis [1],
and is characterized by a combination of arthritis and
systemic inflammation, including fever, rash and serosi-
tis. SJIA has distinct demographic characteristics com-
pared to other JIA subtypes, including onset throughout
childhood and lack of gender preference. At clinical pre-
sentation, SJIA may resemble other diseases in children,
including viral infection and Kawasaki disease [2-4]. The
outcome in SJIA is variable, with close to half of chil-
dren having a monocyclic course, less than 10% having
an intermittent course, and over half having a persistent
course [5,6], the latter often dominated by chronic
arthritis. An adult form of SJIA is called Adult Onset
Still Disease (AOSD) and occurs rarely [7].
There are also unique immunophenotypic features in
SJIA compared to other JIA subtypes, such as the lack of
human leukocyte antigen (HLA) class II allele association,
low or absent autoantibodies (specifically, antinuclear anti-
bodies, rheumatoid factor or anti-CCP antibodies [8]), a
tendency toward monocytosis [9,10], high levels of IL-18
[11,12] and natural killer cell abnormalities in at least a
subset of patients [13]. These immunologic features,
together with the therapeutic efficacy of inhibitors of IL-1
or IL-6 in SJIA and AOSD, suggest that these diseases
might be best classified as autoinflammatory rather than
autoimmune [14-17].
Despite our knowledge of some important immunologi-
cal characteristics of active SJIA, the pathogenesis of SJIA
remains unknown. One of the unanswered questions is
whether independent biological processes underlie the sys-
temic symptoms and the arthritis. Evidence from clinical
studies shows that earlier in the disease, IL-1 inhibitors
(and perhaps also IL-6 blockade) are efficacious, especially
against systemic symptoms, but at a later stage, where
arthritis may predominate, patients may develop resistance
to these therapies [18-20]. These findings suggest that dis-
tinct biological processes may be associated with different
manifestations and/or different stages of the disease.
Transcriptional profiling of peripheral blood cells has
been a useful approach for identifying biological pathways
involved in SJIA and other complex diseases, such as poly-
articular JIA (POLY), rheumatoid arthritis (RA), systemic
lupus erythematosus and Kawasaki disease [21-24].
Previous studies of SJIA using microarray analyses have
revealed transcriptional signatures in peripheral blood asso-
ciated with active disease and with patient subsets [25-29].
We hypothesized that distinct gene expression pat-
terns may be associated with individual clinical para-
meters used as measures of the systemic inflammation
and the arthritis. We analyzed expression in peripheral
blood mononuclear cells (PBMC) of a panel of inflam-
mation-associated genes to determine patterns
associated with elevations in two markers of disease
activity in JIA, erythrocyte sedimentation rate (ESR) and
number of active joints (joint count, JC). ESR is a mar-
ker of inflammation that is elevated in association with
systemic as well as organ-specific inflammation, includ-
ing arthritis [30]. Active joints are defined as joints with
non-bony swelling or limited range of motion, with
either tenderness or pain on motion; we chose active
joint count as a marker of arthritis.
We asked if common or unique expression profiles are
associated with ESR and JC in SJIA. In order to assess
the specificity of our results for SJIA, we also asked
whether the expression of the panel of tested genes dif-
fered in SJIA patients compared to patients with polyar-
ticular course JIA (POLY), which is characterized by
chronic polyarthritis. We then analyzed if JC associated
genes differ during the early and late phase of SJIA.
Based on the gene expression patterns, we identified
candidate biological pathways associated with the sys-
temic and arthritis components of SJIA.
Methods
Subject population and clinical data collection
The study was approved by the Stanford University
Administrative Panel on Human Subjects in Medical
Research (protocol ID 13932). Informed consent was
obtained from patients or parents or guardians before
blood sample collection. Venous blood samples from all
subjects were treated anonymously throughout the analy-
sis. All JIA patients were followed at the Pediatric Rheu-
matology Clinic at Lucile Packard Children’s Hospital.
SJIA and POLY patients met amended ILAR criteria for
diagnosis [1]. Thirty-one SJIA and 18 POLY individual
patients participated in this study. A total of 46 SJIA
samples (22 Flare and 24 Quiescence samples), and 25
POLY samples (17 Flare and 8 Quiescence samples) were
analyzed. Some patients, (SJIA n = 15; POLY n = 7) con-
tributed samples during both flare and quiescent disease
states. Twelve POLY patients were rheumatoid factor
(RF) negative, and six were RF positive. All samples were
classified as flare (F) or quiescence (Q) based on a
scheme we developed for this and other studies of JIA
[10,31,32] (Tables 1, 2 and 3 and [33,34]). SJIA flare sam-
ples had a systemic score of ≥ 1 and/or an arthritis score
of ≥ B (≥ 5 active joints). POLY flare samples had an
arthritis score of ≥ 1 (≥ 1 to 10 active joints). Arthritis
severity is scored differently for SJIA and POLY patients,
because the patterns of joint involvement generally are
different between the two groups [34], with the exception
that some SJIA patients develop POLY-like arthritis with
symmetric, small joint involvement. The arthritis scoring
system is based on frequency analyses of numbers of
active joints in early active SJIA [34] and in active POLY
[Sandborg C, frequency data not shown]. Comprehensive
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clinical information was collected at each patient visit,
including history, physical exam and clinical laboratory
values [10]. As shown in Table 4, and consistent with the
known demographics of JIA [35], SJIA patients are
younger than POLY patients and are gender-balanced,
whereas there are more female than male POLY patients.
As expected, flare (F) patients from both SJIA and POLY
cohorts differ significantly from quiescent (Q) patients
for variables reflecting active inflammation: erythrocyte
sedimentation rate (ESR), white blood cell count (WBC),
platelets (PLT) and joint count (JC, number of affected
joints).
Sample processing
Blood samples were obtained only when there was a clini-
cal need for blood tests. A total of 3 to 4 ml of blood was
collected directly in vacutainer cell preparation tubes
(CPT) with sodium citrate (Becton Dickinson, Franklin
Lakes, NJ, USA). Peripheral blood mononuclear cells
(PBMCs) were isolated within three hours of collection by
centrifugation of CPT tubes, per the manufacturer’s
instructions.
RNA preparation
Purified PBMCs were lysed in RLT reagent (Qiagen,
Valencia, CA, USA) and lysate was stored at -80°C until
RNA extraction. RNA was isolated using the RNeasy mini
kit (Qiagen), per the manufacturer’s instructions with an
additional on-column DNase I (Qiagen) treatment for 40
minutes. The RNA concentration was measured by the
Ribogreen assay (Molecular Probes, Grand Island, NY,
USA) or by absorbance at 260 nm. The purity of RNA was
assessed by the ratio of the absorbance readings at 260
and 280 nm. The integrity of the RNA samples was also
checked by either agarose gel electrophoresis or with the
Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA).
Gene panel selection
In a pilot study, paired flare/remission PBMC samples
from 14 SJIA patients were processed for RNA as
described [36] and analyzed using Lymphochip cDNA
microarrays (Patrick Brown, Stanford University, Stanford,
CA, USA) [37,38]. A large number of genes were identified
as differentially expressed in flare versus remission sam-
ples by Significance Analysis of Microarrays (SAM) [39].
Hierarchical clustering was performed with the Cluster
program and visualized using TreeView [40] (Eisen Lab,
University of California, Berkeley, CA), as illustrated for a
subset of genes in Additional file 1, and also in [36,41].
The full data set, GSE37388, is released to the public on
the Gene Expression Omnibus (GEO) database. From the
large set, we selected genes (n = 131) representing various
ontologic categories, such as signaling, transcription,
inflammation and immune function. We then added other
immune-related genes (n = 50) that are expressed in
PBMC and implicated in JIA or RA by published reports.
The genes were selected prior to analysis of any blood
samples for this study, and the samples used for the
microarray experiment were not re-used here. The 181
selected genes are shown on Additional file 2; we con-
firmed that many are immune-related using the program
PANTHER 7.0 (Protein ANalysis THrough Evolutionary
Relationships) Classification System (Thomas Lab, Univer-
sity of Southern California, Los Angeles, CA, USA), which
classifies proteins by their functions, using published
experimental evidence and evolutionary relationships [42]
(http://www.pantherdb.org/) to categorize their biological
functions. This analysis showed that the largest functional
category is inflammatory chemokine and cytokine
Table 1 Systemic scoring system for SJIA patients.
Score Severity
level
Systemic symptoms
0 None No active disease
1 Mild Having any one of the following: rash, fevers < 10 days in the past month, ESR 40 to 90, platelets > 450,000
2 Moderate Having at least three of the following: rash, fever > 10 days in the past month, WBC > 20,000, ESR > 90, platelets > 550,000, d-
dimers 250 to 500, elevated fibrinogen
3 Severe Having any one of the following symptoms: pneumonitis, percarditis, pleural effusion, Macrophage Activation Syndrome (MAS)
Table 2 Arthritis scoring system for SJIA patients.
Score Severity level Arthritis
A None No joint involvement
B Mild < 5 active joints
C Moderate 5 to 10 active joints
D Severe > 10 active joints
Table 3 Arthritis scoring system for POLY JIA patients*
Score Severity level Arthritis
0 None No joint involvement
1 Mild 1 to 10 active joints
2 Moderate 10 to 20 active joints
3 Severe > 20 active joints
* Arthritis severity is scored differently for SJIA and POLY JIA patients, because
the patterns of joint involvement differ between the two groups [33]. The
arthritis scoring system is based on frequency analyses of numbers of active
joints in early active SJIA [34] and in active POLY JIA [Sandborg C, not shown].
An active joint is defined as a joint with non-bony swelling, or limited range
of motion with either tenderness or pain on motion.
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signaling pathways (14.6% of the genes), followed by inter-
leukin signaling pathways (10.8%), apoptosis signaling
pathways (9.9%) and toll receptor signaling pathways
(6.2%). A full list of categories covered is shown on Addi-
tional file 3.
Gene expression detection by kinetic PCR
The kinetic RT-PCR assay was performed as described
[43]. Briefly, all reactions were carried out in duplicate as
a single-step RT-PCR reaction, using SYBR green chem-
istry. Data from duplicate reactions for each gene were
averaged and normalized based on levels of expression of
four housekeeping genes: eukaryotic translation elonga-
tion factor 1 alpha1 (EEF1A1), protein phosphatase 1,
catalytic subunit, gamma isoform (PPP1CC), ribosomal
protein L12 (RPL12), and ribosomal protein L41
(RPL41). The normalized expression level, housekeeping
normalized units, of each gene was used to determine the
fold change among samples. In a preliminary experiment,
we found that a subset (n = 75) of our gene panel showed
very limited variation in level (± 2-fold difference from
the mean value) in five healthy individuals (two females
and three males) over a four-month period (data not
shown).
Identification of ESR or JC significantly associated genes
in SJIA and POLY
Genes significantly associated with SJIA and POLY were
determined using Pearson’s correlation and Student’s t-
test, as explained in the Results section.
Table 4 Subjects demographic and clinical characteristics
Characteristics SJIA
Flare
SJIA
Quiescence
POLYJIA
Flare
POLYJIA
Quiescence
N1 22 24 17 8
Female/Male2 11/11 11/13 14/3 7/1
African-
American
1 2 1 1
Asian 3 3 0 0
Caucasian 8 10 11 4
Caucasian Hispanic 10 9 5 3
Median age (yr) at disease onset (range) 5.8 (1.7 to 15.7) 5.8 (1.4 to 15.7) 8.6 (1.2 to 15.1) 8.6 (1.2 to 15.1)
Median age (yr) at sample collection (range) 9.3 (3.5 to 16.6) 11.1 (2.4 to 18.9) 13.4 (5 to 18.7) 14.1 (6.1 to 19.2)
Median WBC (x103/ul)
(range)
13.3 (5.3 to 27.4)3 6.9 (3.4 to 11.8) 8.8 (4.9 to 15.1) 7.5 (5.6 to 9.8)
Median platelets (x103/ul)
(range)
461 (257 to 814)4 280 (170 to 400) 384 (211 to 512)5 283 (224 to 432)
Median ESR (mm/h)
(range)
81 (11 to 121)6 5.5 (0 to 18) 31 (7 to 78)7 9 (2 to 15)
Median joint count (range) 9 (1 to 28)8 0 (0 to 1) 25 (3 to 62)9 0 (0)
Median prednisone dose,
mg/kd/day (range)
0.01 (0 to 0.53)10 0 (0 to 1.1) 0 (0 to 0.1) 0 (0 to 1)
Methotrexate/
total no. samples (%)
8/22 (36%) 7/24 (29%) 10/17 (59%) 6/8 (75%)
Anti-TNF/total no. samples (%) 7/22 (32%) 9/24 (38%) 5/17 (29%)11 5/8 (63%)11
IL-1RA/total no. samples (%) 1/22 (5%) 2/24 (8%) 0/17 0/8
F, Flare; Q, Quiescent; SJIA F, systemic score of ≥ 1 and/or an arthritis score of ≥ B; POLY F, arthritis score of ≥ 1 (See Tables 1-3)
WBC: white blood count; ESR: erythrocyte sedimentation rate
1 31 unique SJIA patients, and 18 unique PolyJIA patients; 15 SJIA patients and 7 PolyJIA patients gave samples during flare and quiescence.
2 P < 0.05 (chi-square test)
Tests performed using Kruskal-Wallis with Dunn’s multiple comparison test post test (3 to 9):
3 P < 0.0001 compared to SJIA Q and P < 0.05 compared to Poly Q
4 P < 0.0001 compared to SJIA Q and P < 0.01 compared to Poly Q
5 P < 0.05 compared to SJIA Q
6 P < 0.0001 compared to SJIA Q and P < 0.01 compared to Poly Q
7 P < 0.01 compared to SJIA Q
8 P < 0.0001 compared to SJIA Q and Poly Q
9 P < 0.0001 compared to SJIA Q and Poly Q
10 One patient received intravenous methylprednisolone pulse of 1 g daily for three days at the time of the sample.
11 This difference may reflect inclusion of subsets of patients who are anti-TNF responders and non-responders. This difference also raises the possibility that the
gene signatures could be specifically influenced by differential response to this drug in these groups.
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Significance analysis of the canonical biological pathways
The biological pathways indicated by the group of genes
associated with each clinical parameter/patient cohort
subset were determined by pathway analysis with Ingenu-
ity IPA system (Ingenuity Systems, Redwood City, CA,
USA; http://www.ingenuity.com). The significance of
either ESR or JC related pathways was analyzed using
sparse linear discriminant analysis method, as previously
described [44]. Correlation between SJIA ESR-related
and JC-related pathways was analyzed by Pearson corre-
lation. To determine a threshold to extract pathways that
significantly differentiate ESR and JC in SJIA, 500 simu-
lated SJIA ESR-related and 500 simulated JC-related
pathway data sets were created by permutation of cano-
nical pathway identifications and their associated path-
way P-values for SJIA ESR or JC. For each canonical
pathway, the absolute P-value difference in logarithm
form between SJIA ESR and JC was computed using one
of the 500 simulated SJIA ESR and one of the 500 simu-
lated JC pathway P-value data sets. This led to 500 abso-
lute log P-value differences for each canonical pathway
between SJIA ESR and JC, which later were sorted and
20%, 50% and 80% values were computed. Densities of
the absolute differences between SJIA ESR and JC-related
pathways for the original and the simulated data sets
(20%, 50%, and 80%) were plotted using the R package.
Comparison of the original data set and the 80th percen-
tile simulated data set determined the threshold to select
significantly different pathways between SJIA ESR and
JC. A similar approach was applied to the analysis of sig-
nificantly different pathways between SJIA ESR and
POLY ESR.
Results
ESR and JC-associated gene expression in JIA
ESR was chosen as a quantitative measure of systemic
inflammation for our analysis, as it typically rises in asso-
ciation with flares of systemic symptoms and was assessed
in the largest number of samples. We also considered
another measure of systemic inflammation, C-reactive
protein (CRP), but few samples were assessed for CRP,
precluding the use of this parameter in our analysis. The
number of affected counts (joint count, JC), as defined
above (Introduction), was used as a quantitative measure
of arthritis.
Our samples were initially classified as flare or quies-
cence based on criteria that we have developed for analy-
sis of JIA (Tables 1, 2 and 3), as previously published
[10], and ESR and JC are part of these criteria. We per-
formed a distribution analysis of ESR or JC values by dis-
ease states (flare/quiescence) using R Epicalc package
(http://cran.r-project.org/web/packages/epicalc/) to
investigate if additional subgroups would be revealed.
Visual inspection of the results show that the SJIA and
the POLY flare patients could be partitioned into two
groups related to their ESR values (Figure 1A): F1, with
ESR values below 20, and F2, with ESR values above 20.
All patients in the F1 subgroup had mild flares by our
other criteria (not shown). Quiescence samples all had
ESR below 20, clustering together with the F1 flare
group. This analysis also showed that, in our samples, JC
values in the flare and quiescence disease states are gen-
erally non-overlapping in both SJIA and POLY patients,
with quiescence samples with 0 or 1 joint count, and all
flare samples above zero (Figure 1B).
We analyzed the association of the 181 gene panel with
ESR and JC in both SJIA and POLY samples, using the
strategies delineated in Figure 2. Genes whose expression
was significantly associated with ESR or JC in SJIA and
POLY cohorts were identified in two ways. As described
in Figure 2A, Pearson correlation analyses were performed
to correlate ESR or JC values with patient expression data
sets. To assess the significance of these findings, we calcu-
lated the global false discovery rate (gFDR) by 100-fold
permutation of normalized kPCR data. After determining
the gFDR, local FDR (lFDR) analysis can compute and
assign significance measures to all features [45]. A cut-off
value of lFDR ≤ 0.05 was used to select significant genes
for downstream pathway analysis.
We also analyzed gene expression association using
Student’s t-test, as shown in Figure 2B. For ESR, based
on the analysis from Figure 1A, we initially divided our
samples into three groups: flare samples with ESR < 20
(F1), flare samples with ESR > 20 (F2), and quiescence (to
ensure that differences between F1 and Quiescence were
not overlooked). We identified genes whose mean
expression value differed significantly between the F1
(ESR < 20) and F2 (ESR > 20) patient groups, but no dif-
ferences in genes expressed by the F1 and the quiescence
group were found. Subsequently, we grouped the flare F1
and the quiescence groups into one group for ESR analy-
sis. For JC, no other partitioning was necessary, as shown
in Figure 1B, and samples were grouped into flare and
quiescence groups. As we did previously for Pearson ana-
lysis, we calculated local FDR and a value of < 0.05 was
considered significant (Figure 2B). This second analysis
found genes missed by correlation analysis, as the latter
requires a linear relationship and captures genes with
more tightly regulated expression (small differences
between F and Q samples).
Pearson correlation analysis of expression data from
SJIA subjects found 79 genes from our panel to be ESR-
correlated and 36 genes to be JC-correlated. Student’s
t-test found 66 ESR-associated and 79 JC-associated genes
in SJIA. This pattern differed from relationships of the
expression levels of the same genes with these clinical
parameters in POLY-course JIA patients: 20 ESR-corre-
lated and no JC-correlated genes were found in POLY,
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and none of the genes were ESR-associated or JC-asso-
ciated by Student’s t-test in POLY. Combining both ana-
lyses, we found 91 ESR-related and 92 JC-related genes in
SJIA, and 20 ESR-related and no JC-related genes in
POLY. A list of significantly associated genes is on Addi-
tional file 4. Additional file 5 (Supplementary Figure 2A-F)
diagrams the fold changes in expression of the selected
genes between groups (for example, F2 versus F1 + Q)
and between quartiles of ESR or JC. The probability
density analysis graphically represents the normalized fre-
quency distribution of the fold ratio of the selected two
groups. This result indicates that our selected genes have
significant variation between groups (limited variation =
fold ratio close to 1) while showing strong association.
This analysis further supports our approach (Figure 2) for
the identification of significant associations. The reduced
number of genes associated with these clinical parameters
in the POLY cohort was not surprising given that the gene
ESR
Q
F
SJIA  F
SJIA  Q
F1 F2
Q
F
ESR
POLY    F
POLY   Q
F1 F2
Q
F
SJIA  F
SJIA  Q
JC
POLY  F
Q
F
POLY  Q
JC
A
B
Figure 1 Distribution of ESR or JC values by Flare (F) or Quiescence (Q) disease states. (A) The SJIA/POLY F patients are partitioned into
two groups (F1 and F2) by ESR value < 20. (B) SJIA/POLY JC values are generally non-overlapping, in accordance with the F and Q disease
states.
JC/ESR data 
Gene  data
JC/ESR/Gene data set + 100
permuted gene data set  
Pearson Correlaon analysis 
FDR analysis
Correlate ESR data 
to gene dataSJIA samples (n = 46)
POLY samples (n = 25)
       Gene (n = 181) Correlate JC data 
to gene data
ESR correlated genes
JC correlated genes
Gene data set + 100
permuted gene data set  
Student ‘s t test
FDR analysis
JC associated genes:
F vs. Q signiﬁcantly diﬀerent genes 
ESR associated genes:
F1 vs. Q not signiﬁcantly &
F1+Q vs. F2 signiﬁcantly diﬀerent genes ESR <20, Flare = F1
ESR >20, Flare = F2
Quiescence = Q
Paents samples
paron 
into 3 groups
ESR: Compare F1  + Q vs. F2
JC: Compare F vs. Q
A
B
Figure 2 Schematic of the experimental design and result summary. (A) Pearson correlation analysis and (B) Student’s t-test were used to
identify ESR or JC associated genes in SJIA and POLY.
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list was chosen in large part using expression data from
SJIA PBMC. Indeed, this finding implies a degree of speci-
ficity of the associated genes for SJIA (see discussion).
Another likely contribution to this difference might be the
extent that disease-related processes are reflected in per-
ipheral blood in the two disease types.
Comparative analysis of SJIA ESR and JC related
pathways
Using the lists of associated genes, we determined biologi-
cal pathways associated with each clinical parameter/
patient cohort by pathway analysis with the Ingenuity IPA
system. ESR-related and JC-related pathways were then
compared, to investigate whether the same biological path-
ways are involved in ESR and JC elevations in SJIA. As
shown in Figure 3A, there is strong correlation (Pearson
correlation coefficient, 0.91) between SJIA ESR and JC-
related pathways (n = 189), implying that some of the
same pathways play roles in the systemic and arthritic
components of the disease. Shown in Figure 3B, densities
of the absolute log P-value differences of all pathways
between SJIA ESR and JC, for the original and the 20, 50
and 80 percentile of the simulated random data sets, were
computed and plotted.
Significantly differentiating pathways between ESR and
JC in SJIA revealed by this analysis are in Table 5 (top two
pathways), as were pathways that were correlated compar-
ably with both ESR and JC (Table 5). The only pathway
more significantly related to SJIA ESR than to SJIA JC was
the glucocorticoid (GC) receptor signaling pathway. The
expression of most of the genes in this pathway was higher
in samples with higher ESR compared to samples with
lower ESR. In contrast, the PI3K/Akt signaling pathway
was more significantly related to SJIA JC. Though the sig-
nificance of the association favored JC, the expression
levels of most genes in this cell survival pathway were
higher in samples with higher ESR or higher JC. However,
as might be expected, TP53, which encodes p53, a pro-
apoptotic, negative regulator of the Akt pathway [46], was
down-regulated in association with JC and ESR elevations.
Consistent with these results, we have previously reported
that purified monocytes have lower TP53 transcript levels
and increased cellular resistance to apoptotic stimuli dur-
ing SJIA flare compared to quiescence [36]. Overall, the
identification of some pathways that are differentially cor-
related with ESR and JC raises the possibility of differences
in aspects of the immunobiology of arthritis compared to
systemic inflammation in SJIA, as discussed below.
A number of pathways were significantly related to SJIA
ESR and JC to the same degree (Table 5). For several of
these pathways, the expression of most of the associated
genes was higher in samples with higher ESR or JC. These
pathways include, among others, protein kinase receptor
(PKR, a pattern-recognition receptor) signaling in
interferon induction, T cell and B cell signaling in the pat-
tern of rheumatoid arthritis (RA), and (macrophage)
migration inhibition factor (MIF) regulation of innate
immunity. Other genes in pathways associated with acti-
vating innate responses, such as lipopolysaccharide (LPS)
signaling and triggering receptor expressed on myeloid
cells (TREM1) signaling are also higher samples with
either higher ESR or JC. Genes in other pathways showed
lower expression in samples with higher ESR or JC, such
as T helper cell differentiation, iCOS-iCOSL (inducible T-
cell co-stimulator/ligand) signaling in T helper cells and
CD40 (co-stimulatory molecule on antigen presenting
cells) signaling. Notably, these down-regulated pathways
are associated with adaptive immune responses. Also
down-regulated in association with elevations of both SJIA
ESR and JC is the pathway for crosstalk between dendritic
cells and natural killer cells, which can be involved in
restriction of innate responses [47].
Two genes, the DNA repair enzyme ATM and the tran-
scription factor NFATC2 (also known as NFAT1), are in
the pathway for RANK signaling in osteoclasts and are
both down-regulated in association with systemic (ESR)
and arthritic (JC) disease activity. The Rank/RankL path-
way is an important regulator of bone remodeling [48]. An
ATM deficiency has been described in CD4+ T cells from
rheumatoid arthritis (RA) patients [49], associated with
premature immunosenescence. However, ATM may also
be involved in bone formation, and ATM deficient animals
show increased numbers of osteoclasts [50]. The transcrip-
tion factor NFATC2 has been identified as a negative reg-
ulator of cartilage cell growth [51]. It is also important in
T cell effector function, translocating to the nucleus fol-
lowing T cell receptor activation and regulating expression
several cytokines in CD4 T cells (reviewed in [52]). Thus,
its inverse correlation with ESR and JC may be similar to
the other T cell-related pathways described above. Inter-
estingly, hyperactivation of NFATC2 in T cells is asso-
ciated with decreased susceptibility to experimental
autoimmune encephalomyelitis, indicating that increased
NFATC2 activity may have immunomodulatory effects
that down-regulate autoaggressive reactions [53].
Comparative analysis of SJIA and POLY ESR-related
pathways
We next asked whether some biological pathways
involved in SJIA ESR elevation are also involved in POLY
ESR elevation, by comparing SJIA and POLY ESR-related
genes. As shown in Figure 3C, there is reduced correla-
tion (correlation coefficient, 0.59) between SJIA and
POLY ESR-related pathways (n = 119), compared to the
correlation we observed between SJIA ESR- and SJIA JC-
related pathways. Shown in Figure 3D, densities of the
absolute logarithm P-value differences of all pathways
between SJIA and POLY ESR, for the original and the 20,
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50 and 80 percentile of the simulated random data sets,
were computed and plotted.
Several pathways differ significantly between SJIA and
POLY ESR, as quantified by absolute difference between
the SJIA and POLY pathways (Table 6). These include:
the role of macrophages, fibroblasts and endothelial
cells in RA, IL-10 signaling, glucocorticoid receptor sig-
naling, among others. These data suggest a greater role
for these pathways in SJIA, compared to POLY. How-
ever, very few genes were associated with POLY ESR in
most pathways, resulting in low significance of associa-
tion with POLY (not shown). In these differentiating
pathways, the (few) genes correlating with ESR were
higher in POLY samples with higher ESR values, sug-
gesting that these genes, perhaps in the context of other
pathways or in the context of the identified pathways
but within the joint, contribute to inflammation in poly-
articular course JIA. Indeed, evidence from RA, the
adult disease most similar to polyarticular JIA, impli-
cates monocyte and macrophage activation [54] and
endothelial cell dysfunction [55], both in joints and in
the periphery.
As observed in the previous analysis, pathways asso-
ciated with T cell responses are significantly associated
with ESR in SJIA but the genes in these pathways show
lower expression in samples with higher ESR in compari-
son to samples with lower ESR. In addition, this analysis
showed that genes in B cell activating factor (BAFF) sig-
naling, April (A proliferation-inducing ligand, TNFSF13)-
mediated signaling and IL-15 signaling pathways show
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Figure 3 Analyses of biological pathways associated with SJIA ESR, SJIA JC and POLY ESR. Comparative analyses determine pathways that
are significantly different in their association with SJIA ESR vs JC (top panels) or that differentiate SJIA/ESR and POLY/ESR cohorts (bottom
panels). (A) Pearson correlation analysis between SJIA ESR and JC related pathways identified by Ingenuity Analysis. (B) Simulation analyses to
determine the threshold for significantly differentiating pathways between ESR and JC in SJIA. Densities of the absolute differences between SJIA
ESR- and JC-related pathways, for the original and the simulation data sets (20%, 50% and 80%) are shown. See Methods for more details. (C)
Pearson correlation between SJIA and POLY ESR-related pathways identified by Ingenuity Analysis. (D) Simulation analysis to determine the
threshold for significantly differentiating pathways between SJIA and POLY ESR, performed as in (B).
Ling et al. BMC Medicine 2012, 10:125
http://www.biomedcentral.com/1741-7015/10/125
Page 8 of 15
lower expression samples with in elevated ESR in SJIA
(Table 6).
Comparative analysis of joint count (JC) correlated genes
in systemic and arthritis phase (SAF) and arthritis phase
(AF) SJIA patients
Using the previously identified JC-associated genes (Addi-
tional file 4), we then investigated whether arthritis-related
gene pathways change when the disease phenotype
changes from the earlier systemic and arthritic activity/
flare (SAF) phase to arthritis-only activity/flare (AF) phase.
Shown in Figure 4A, SJIA patients were distributed
according to values of JC and systemic scores (Tables 1
and 2-) to identify SAF and AF subgroups. Figure 4B
shows the JC associated genes that are significantly corre-
lated with JC in SAF and AF subgroups. Within the SJIA
SAF group, only IL-10 was identified to positively correlate
with JC (P-value 0.026). In contrast, 12 genes were found
to significantly correlate (negatively) with JC in AF sub-
group (Figure 4B, listed in order of decreasing
significance): TRAP1, IL2RG, CD40LG, PARP1, TP53,
ATM, NFATC2, GZMA, CASP10, PFKFB3, IRF3 and
IRF4. Canonical pathway analysis (Figure 4C) mapped 8 of
the 12 JC-correlated genes to a single network with the
Th2 cytokine, IL-4, at its center. These functional relation-
ships suggest that lack of IL-4 may contribute to arthritis
in the AF subgroup. The difference in JC-correlated
genes/pathways between AF and SAF supports the
hypothesis that different biological pathways are engaged
in the chronic arthritis stage versus the more acute (or sys-
temic symptom-associated) arthritis of SJIA.
Discussion
In this study, we sought to identify molecular pathways
involved in the systemic and arthritic components of SJIA
by investigating the gene expression pathways associated
with increases in ESR and active joint count. We chose
ESR as a marker of systemic inflammation, but we note
that SJIA flares associated with elevated ESR may also
include arthritis. Further, SJIA flares with macrophage
Table 5 Biologic pathways that distinguish or are shared between SJIA ESR and SJIA JC
IPA Canonical Pathways -Logarithm
(P-value)
Difference
(ESR-JC)
Gene expression with higher ESR/JC*
SJIA ESR SJIA JC
Glucocorticoid receptor signaling 5.68 3.07 2.61 Higher (both)
PI3K/AKT signaling 1.27 3.73 -2.45 Higher (both)
Role of PKR in interferon induction and antiviral response 4.43 4.43 0 Higher (both)
Altered T cell and B cell signaling in rheumatoid arthritis 3.91 3.91 0 Higher (both)
T helper cell differentiation 3.74 3.74 0 Lower (both)
iCOS-iCOSL signaling in T helper cells 3.73 3.73 0 Lower (both)
CD40 signaling 3.73 3.73 0 Lower (both)
MIF regulation of innate immunity 3.70 3.70 0 Higher (both)
LPS-stimulated MAPK signaling 3.42 3.42 0 Higher (both)
CD27 signaling in lymphocytes 3.18 3.18 0 Higher (both)
MIF-mediated glucocorticoid regulation 3.02 3.02 0 Higher (both)
Role of cytokines in mediating communication between immune cells 3.01 3.01 0 Higher (both)
TREM1 signaling 2.91 2.91 0 Higher (both)
Crosstalk between dendritic cells and natural killer cells 2.81 2.81 0 Lower (both)
Docosahexaenoic acid (DHA) signaling 2.76 2.76 0 Higher (both)
Regulation of IL-2 expression in activated and anergic T lymphocytes 2.39 2.39 0 Higher (both)
Toll-like receptor signaling 2.37 2.37 0 Lower (both)
fMLP signaling in neutrophils 2.33 2.33 0 Higher (both)
TNFR1 signaling 2.22 2.22 0 Higher (both)
RANK signaling in osteoclasts 2.16 2.16 0 Lower (both)
4-1BB signaling in T lymphocytes 2.12 2.12 0 Higher (both)
CD28 signaling in T helper cells 2.11 2.11 0 Lower (both)
Communication between innate and adaptive immune cells 2.06 2.06 0 Higher (both)
T cell receptor signaling 2.03 2.03 0 Lower (both)
ILK signaling 2.01 2.01 0 Higher (both)
* in ≥ 50% of the genes in the pathway; in comparison to lower ESR/JC.
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activation syndrome (MAS) may actually lower ESR from
fibrinogen consumption as part of the coagulopathy [56].
The latter issue does not confound our analysis, as the
three flare samples with low ESR were from patients with
mild flares without MAS. Strictly speaking, our approach
delineated gene associations with ESR; however, in our
group of SJIA samples, ESR typically correlated closely
with other evidence of systemic disease.
Several variables that influence transcriptional profiles
should be considered in relation to our results. It is possi-
ble that some of the observed differences in gene expres-
sion are due to differences in cell type composition of
PBMC between SJIA and POLY, or between flare and
quiescence [10]. Changes in abundance of cell types may
be relevant to disease mechanisms. For monocyte-related
genes, we [41] and others [9] have shown that the differ-
ences in transcript abundance are not explained by differ-
ences in monocyte numbers alone, but reflect activation
state. The use of medication and disease duration at the
time of sampling may influence the pattern of gene
expression. A larger, likely multi-center, study will be
needed to rigorously control for these important
variables.
Our analysis revealed overlap in molecular pathways
involved in increased ESR and elevated JC in SJIA. This
result was not unexpected, given reported correlations
between these two parameters [30,57]. However, the
glucocorticoid receptor (GCR) signaling pathway was
more significantly related to ESR than JC. Systemic
symptoms of SJIA respond to exogenous steroids, sug-
gesting the elevation of GCR signaling may represent an
endogenous effort to dampen systemic inflammation.
The comparable doses of exogenous steroids in the F and
Q groups make it less likely that steroid therapy is indu-
cing this pathway. Notably, polymorphism in the GCR
gene is associated with the level of inflammatory activity
in JIA [58]. Involvement of GCR signaling in systemic
inflammation in SJIA and stronger association of this
pathway with inflammation in SJIA versus POLY (at least
as reflected in blood cells) is consistent with reduced
responses in SJIA patients to non-glucocorticoid drugs
that are efficacious in subsets of POLY patients (for
example, methotrexate and anti-TNFa [59,60]).
We also found that the PI3K/Akt signaling pathway is
more significantly related to SJIA JC than ESR. This path-
way, which is activated by a variety of stimuli, including
IL-1b, TNFa and IL-6, is potentially involved in IL-17 pro-
duction [61]. IL-17 could be an important factor in SJIA
arthritis [19], particularly in the later phase. We did not
assess expression of IL-17 in this study, but our prelimin-
ary data suggest that CD4+ T cells from SJIA patients
secrete higher levels of IL-17 than control cells when cul-
tured in TH17-polarizing conditions [Wong M, Mellins E,
unpublished results]. Recently, enrichment of Th17 (and
Table 6 Biologic pathways that distinguish or are shared between SJIA ESR and POLY ESR
IPA Canonical Pathways -Logarithm
(P-value)
Difference
(SJIA-POLY)
Gene expression with higher
SJIA ESR/
POLY ESR
SJIA ESR POLY ESR
IL-10 signaling 8.56 4.22 4.34 Higher (both)
Role of macrophages, fibroblasts and endothelial cells in rheumatoid arthritis 6.80 1.14 5.65 Higher (both)
Role of osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis 5.84 0.82 5.01 Higher (both)
Glucocorticoid receptor signaling 5.68 1.34 4.34 Higher (both)
B cell receptor signaling 5.60 2.07 3.53 Higher (both)
Role of PKR in interferon induction and antiviral response 4.43 0.86 3.56 Higher (both)
Systemic lupus Erythematosus signaling 4.08 0.46 3.62 Higher (both)
altered T cell and B cell signaling in rheumatoid arthritis 3.91 1.34 2.57 Higher (both)
A proliferation-inducing ligand mediated signaling 3.80 0.95 2.86 Lower (both)
IL-15 signaling 3.76 0.76 3.01 Lower (both)
T helper cell differentiation 3.74 0.00 3.74 Lower (both)
iCOS-iCOSL signaling in T helper cells 3.73 0.51 3.22 Lower (both)
CD40 signaling 3.73 0.75 2.98 Lower (both)
B cell activating factor signaling 3.70 0.93 2.77 Lower (both)
Dendritic cell maturation 3.65 0.94 2.71 Higher (both)
IL-12 signaling and production in macrophages 3.08 0.52 2.55 Lower (both)
p38 MAPK signaling 3.08 0.52 2.55 Higher (both)
PPAR alpha/RXR alpha activation 2.96 0.42 2.55 Higher (both)
* in ≥ 50% of the genes in the pathway; in comparison to lower SJIA ESR/POLY ESR.
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Th1) cells in blood of SJIA patients has been described
[62].
Our findings are consistent with the hypothesis that
dysregulation of the innate immune system makes a
more prominent contribution to SJIA immunopathology
than alterations of the adaptive immune system [17,63],
whereas adaptive responses are thought to drive oligoar-
ticular and polyarticular JIA [64,65]. However, our results
implicate deficiencies in genes associated with T cell-
related responses in SJIA pathology, similar to observa-
tions in other studies [29]. For example, reduced cytolytic
cell activity [66] and diminished function of T regulatory
cells may play roles in SJIA etiology [67]. Down-regulated
genes associated with cytolytic function also participate
in dendritic cell/NK cell and monocyte/NK cell interac-
tion. Some cytolysis genes are part of the IL-15 signaling
pathway, and IL-15 is involved in the development of NK
cells [68].
In the systemic plus arthritic stage of SJIA, we found
that expression of IL-10 in PBMC was positively asso-
ciated with arthritis. In in vitro studies of SJIA monocytes,
we and others [26,29] observe that IL-10 is expressed after
TLR stimulation, and IL-10 signaling is intact [Macaubas
et al., unpublished]. Given the immunosuppressive effect
of IL-10, association of this gene with arthritis in SJIA may
represent an attempt by the immune system to reduce
inflammation. The level of IL-10 may be inadequate to
deal with the inflammatory challenge, as the frequency of
a promoter allele associated with low IL-10 expression is
increased in SJIA patients [69,70]. We found that LPS-
induced production of IL-10 protein in SJIA monocytes is
comparable to controls [41].
A striking finding of this study is that deficiency in IL-
4-related pathways correlates with JC in the arthritic
phase of SJIA. IL-4 has been implicated in protection
against arthritis. Polymorphism in the IL4Ra gene that
A
F
SA
F
Systemic score
Jo
in
t c
ou
nt
 (J
C)
Gene P value
Correlaon 
Coeﬃcient
SAF IL10 0.026 0.87
AF
TRAP1 0.001 -0.99
IL2RG 0.004 -0.98
CD40LG 0.006 -0.97
PARP1 0.009 -0.96
TP53 0.010 -0.96
ATM 0.016 -0.94
NFATC2 0.016 -0.94
GZMA 0.019 -0.94
CASP10 0.020 -0.93
PFKFB3 0.022 0.93
IRF3 0.031 -0.91
IRF4 0.042 -0.89
A
B
C
Legend
Figure 4 Analysis of JC-associated genes in SJIA patients with high JC counts but different systemic scores. (A) Distribution analysis of
SJIA patients, according to both joint count (JC) and systemic scores, established systemic plus arthritis flare (SAF) and arthritis flare (AF)
subgroups. (B) Pearson correlation analysis relating JC values to the associated gene expression in both the SAF and AF subgroups. (C) Pathway
analysis of the JC correlated genes in AF subgroup. Differentially JC-correlated genes were analyzed using data mining software (Ingenuity
Systems) to identify relevant biological pathways associated with each clinical subgroup. The node color indicates the degree of positive (red) or
negative (green) correlation to SJIA AF. Nodes are displayed using shapes that represent the functional class of the gene product and different
relationships are represented by line type (see legend). Relationships are primarily due to co-expression, but can also include phosphorylation/
dephosphorylation, proteolysis, activation/deactivation, transcription, binding, inhibition, biochemical modification.
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confers reduced responsiveness to IL-4 is associated
with worse outcome in RA [71]. Low levels of circulat-
ing IL-4 are observed in patients with active POLY [72].
IL-4 has been shown to suppress growth factor-induced
proliferation of cultured rheumatoid synovial cells by
interfering with the cell cycle and by decreasing cell sur-
vival [73]. In the murine model of collagen-induced
arthritis, IL-4 is protective against cartilage and bone
destruction [74], and neutralization of IL-4 in the same
model results in reversal of arthritis suppression [75].
IL-4 is also protective in the model of proteoglycan-
induced arthritis [76]. Interestingly, in proteoglycan-
induced arthritis, mice deficient in IL-4Ra showed
higher IL-1b, IL-6 and MIP1a, whereas levels of IFNg
and autoantibodies were less affected. These results
imply that IL-4 suppresses innate immune activity more
than the adaptive system in this arthritis model [77].
This might model the arthritis of late stage SJIA.
IL-4 inhibits expression of pro-inflammatory cytokines,
such as IL-1b, TNFa [78,79] and IL-17 [80]. As men-
tioned, IL-17 is an attractive candidate for a driver of
inflammation in the later arthritic phase of SJIA. Th17
cells may become IL-1 independent in SJIA, as seen in an
animal model [81]. The IL-1b independence of IL-17
action would be consistent with the decreased efficiency
of anti-IL1 therapy in the later arthritic phase of SJIA
[19]. The ability of IL-4 to suppress reactivation of com-
mitted Th17 cells [82] may be another mechanism by
with IL-4 deficiency could contribute to arthritis in SJIA.
Finally, in a small, open label study, oral histone deacety-
lase inhibitors in patients with mean SJIA duration of five
years showed significant therapeutic benefit, specifically
for arthritis [83]. This finding is consistent with the idea
that distinct biology may be involved in later phase
arthritis in SJIA.
We found no gene association or correlation linked with
POLY joint count, and a limited number of somewhat dif-
ferent genes were associated with elevated ESR in POLY-
JIA subjects. Our gene panel was largely derived from a
SJIA-based microarray study and, as such, it has a signifi-
cant bias towards SJIA-related genes. Further, the systemic
nature of SJIA predicts more changes in peripheral blood
than for POLY, where pathology is more localized. Our
POLY cohort was itself heterogeneous, including RF+ and
RF- patients, which were analyzed as one group. Most
gene expression studies have analyzed RF- patients only
[29,84,85]; some have not determined the RF status [86].
Griffin et al. 2009 showed that RF+ and RF- patients can
share a similar gene signature [21].
It will be of interest to determine the cell type within
PBMC that is responsible for particular transcripts.
Based on correlated expression patterns with more line-
age specific genes, it is most likely that IL-4 transcripts
derive from CD4 T cells; the IL-4 message expression is
correlated with expression of CD40LG and IL2RG (not
shown). In contrast, the IL-10 expression correlates with
expression of IL-1, IL-1-related genes and IL-6 (not
shown), suggesting IL-10 transcripts are expressed in
monocytes. Further studies are also needed to determine
the specificity of the SJIA gene signature in relation to
other acute inflammatory diseases, such as bacterial and
viral infections and other rheumatologic pediatric
diseases [27]. Nonetheless, our current results add to
the growing evidence that different molecular mechan-
isms distinguish SJIA from other JIA subtypes
[10,11,26,29,32].
Conclusions
This study demonstrates that analysis of individual clinical
parameters in a complex disease like SJIA may reveal
unique and informative molecular associations. In addition
to elucidating disease immunopathology, this approach
may help identify therapeutic targets and strategies tai-
lored to the different phases of SJIA.
Additional material
Additional file 1: Supplementary Figure 1. Unsupervised hierarchical
clustering analysis of a subset of differentially expressed genes from SJIA
flare and quiescence samples studied by microarray. Paired samples from
14 subjects at flare (red) and quiescence (green) were studied.
Independent samples from the same individual are indicated by *. Each
column represents a separate sample; each row represents a separate
gene.
Additional file 2: Supplementary Table 1. The 181 immune-related
genes analyzed in this study.
Additional file 3: Supplementary Table 2. Annotation of the 181
analyzed genes into different functional categories using PANTHER
software.
Additional file 4: Supplementary Table 3. SJIA ESR, SJIA JC and POLY
ESR related gene lists.
Additional file 5: Supplementary Figure 2. The fold changes in
expression of the genes that differ between groups and between
quartiles of ESR or JC. (A) The probability density of fold changes with
the selected ESR-related genes between F1 + Q and F2 of SJIA; (B) The
probability density of fold changes with the selected ESR-related genes
between quartiles (the first quartile to the third quartile) of SJIA; (C) The
probability density of fold changes with the selected JC-related genes
between Q and F of SJIA; (D) The probability density of fold changes
with the selected JC- related genes between quartiles (the first quartile
to the third quartile) of SJIA; (E) The probability density of fold changes
with the selected ESR-related genes between F2 and F1 + Q of POLY; (F)
The probability density of fold changes with the selected ESR-related
genes between quartiles (the first quartile to the third quartile) of POLY.
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